Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-4.17% $2.30
America/New_York / 18 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 32.43 mill |
EPS: | -2.72 |
P/E: | -0.850 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 14.10 mill |
Avg Daily Volume: | 0.106 mill |
RATING 2024-04-18 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.850 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.14x |
Company: PE -0.850 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.69 (16.96%) $0.390 |
Date: 2024-04-18 |
Expected Trading Range (DAY) |
---|
$ 2.06 - 2.54 ( +/- 10.35%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Zeronda Tyler | Sell | 94 | Common Stock |
2024-04-01 | Stuart Iain | Sell | 157 | Common Stock |
2024-04-01 | Harsch Mutya | Sell | 161 | Common Stock |
2024-04-01 | Domzalski David | Sell | 1 004 | Common Stock |
2024-01-01 | Zeronda Tyler | Buy | 62 500 | Common Stock |
INSIDER POWER |
---|
-56.79 |
Last 99 transactions |
Buy: 3 356 313 | Sell: 7 897 303 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.30 (-4.17% ) |
Volume | 0.0109 mill |
Avg. Vol. | 0.106 mill |
% of Avg. Vol | 10.34 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.